The Protein Tomography(TM) Award Now Published on Sidec's Homepage

STOCKHOLM, May 26/PRNewswire/ -- Sidec announces that the application form for the 2008 Protein
Tomography(TM) Award is now available at Sidec's homepage. The winning
application will be offered a Protein Tomography(TM) study in collaboration
with Sidec. A Protein Tomography(TM) study is typically in the range of 0.1
and 0.5 million Euro and will be funded by Sidec.

(Logo:
http://www.newscom.com/cgi-bin/prnh/20080220/294289 )

The Protein Tomography(TM) Award 2008 is given to acknowledge innovative
project ideas in the areas of protein therapeutics and antibody drug
development.

A committee chaired by Sidec's CSO Dr. Anders Aberg will select the
winning Protein Tomography(TM) project according to the following criteria:

- Biological question of scientific significance and/or commercial
relevance

- Strategically important for the applying company

- With the aim to be published at a time mutually agreed upon

- Technically suitable for Protein Tomography(TM)

Only research groups in the biopharmaceutical industry who have not yet
worked with Sidec are eligible for the Award to get acquainted with Protein
Tomography(TM).

Please visit http://www.sidec.com to apply. Deadline for Application is
July 31, 2008

"I had an excellent experience collaborating with Sidec and utilizing
their Protein Tomography(TM) technology. I welcome this Award as a positive
step to expose research groups in the biopharmaceutical industry to this
revolutionary technology. At UCB we used Protein Tomography(TM) to image the
synaptic vesicle of protein 2A in situ. To my knowledge this is the only
method available today where it is possible to visualize 3-D images of
individual molecules in situ," says Berkley Lynch, previously Principal
Investigator at UCB.

About Sidec AB:

Sidec studies molecular interactions in situ and in vitro using its
proprietary technology Protein Tomography(TM). Sidec offers collaborative
research projects to the biopharmaceutical industry that reveal unique
information to prioritize the most promising therapeutic antibody and to
locate the antibody binding epitope.

http://www.sidec.com

Photo:
http://www.newscom.com/cgi-bin/prnh/20080220/294289

Source: Sidec AB

For more information, please contact: Hans Johansson, CEO, Phone: +46(0)8-4777-602, E-mail: hans.johansson@sidec.com

2008-05-26 12:08:28 0370086 PRNEWSWIRE